Aimed at sharpening its focus on Dextenza (dexamethasone ophthalmic insert) 0.4 mg, Ocular Therapeutics (NASDAQ:OCUL) initiates a restructuring initiative that, it says, will save ~$11M in annual operating costs. It has not as yet specified the exact number of job cuts, but it will record a $0.7M charge this quarter for related expenses.
Shares up 3% after hours.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.